JP2024512558A5 - - Google Patents
Info
- Publication number
- JP2024512558A5 JP2024512558A5 JP2023558347A JP2023558347A JP2024512558A5 JP 2024512558 A5 JP2024512558 A5 JP 2024512558A5 JP 2023558347 A JP2023558347 A JP 2023558347A JP 2023558347 A JP2023558347 A JP 2023558347A JP 2024512558 A5 JP2024512558 A5 JP 2024512558A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- combination agent
- inhibitor
- months
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166295P | 2021-03-26 | 2021-03-26 | |
| US63/166,295 | 2021-03-26 | ||
| US202163208728P | 2021-06-09 | 2021-06-09 | |
| US63/208,728 | 2021-06-09 | ||
| PCT/EP2022/057895 WO2022200557A1 (en) | 2021-03-26 | 2022-03-25 | Combination treatments for melanoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512558A JP2024512558A (ja) | 2024-03-19 |
| JP2024512558A5 true JP2024512558A5 (enExample) | 2025-04-02 |
Family
ID=81449142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023558347A Pending JP2024512558A (ja) | 2021-03-26 | 2022-03-25 | 黒色腫のための組み合わせ治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197748A1 (enExample) |
| EP (1) | EP4313057A1 (enExample) |
| JP (1) | JP2024512558A (enExample) |
| KR (1) | KR20230162030A (enExample) |
| AU (2) | AU2022245277B8 (enExample) |
| BR (1) | BR112023019433A2 (enExample) |
| CA (1) | CA3213407A1 (enExample) |
| IL (1) | IL306028A (enExample) |
| MX (1) | MX2023011332A (enExample) |
| TW (1) | TW202304458A (enExample) |
| WO (1) | WO2022200557A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021269764A1 (en) * | 2020-05-11 | 2023-01-19 | Astrazeneca Ab | ATR inhibitors for the treatment of cancer |
| WO2025233224A1 (en) * | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
| IL321966A (en) * | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| AU2021269764A1 (en) * | 2020-05-11 | 2023-01-19 | Astrazeneca Ab | ATR inhibitors for the treatment of cancer |
-
2022
- 2022-03-25 IL IL306028A patent/IL306028A/en unknown
- 2022-03-25 BR BR112023019433A patent/BR112023019433A2/pt unknown
- 2022-03-25 AU AU2022245277A patent/AU2022245277B8/en active Active
- 2022-03-25 CA CA3213407A patent/CA3213407A1/en active Pending
- 2022-03-25 JP JP2023558347A patent/JP2024512558A/ja active Pending
- 2022-03-25 US US18/552,300 patent/US20240197748A1/en active Pending
- 2022-03-25 WO PCT/EP2022/057895 patent/WO2022200557A1/en not_active Ceased
- 2022-03-25 EP EP22719807.4A patent/EP4313057A1/en active Pending
- 2022-03-25 TW TW111111247A patent/TW202304458A/zh unknown
- 2022-03-25 KR KR1020237036562A patent/KR20230162030A/ko active Pending
- 2022-03-25 MX MX2023011332A patent/MX2023011332A/es unknown
-
2025
- 2025-10-16 AU AU2025252564A patent/AU2025252564A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2017529382A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| JP2020500152A5 (enExample) | ||
| JP2006513184A5 (enExample) | ||
| JP2018514510A5 (enExample) | ||
| JP2022509262A5 (enExample) | ||
| JP2022019973A5 (enExample) | ||
| JP2009501801A5 (enExample) | ||
| AU2021319090A1 (en) | Treatment of migraine | |
| JP2020502261A5 (enExample) | ||
| JPWO2020250915A5 (enExample) | ||
| Dunne et al. | A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270) | |
| JP2023549849A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| BG60400B2 (bg) | Синергитични фармацевтични препарати, тяхното получаване и употребата им | |
| JP2024535880A5 (enExample) | ||
| Sobieraj et al. | Dimethyl fumarate: A fumaric acid ester under investigation for the treatment of relapsing-remitting multiple sclerosis. | |
| JP2006508118A5 (enExample) | ||
| RU2180591C2 (ru) | Средство для лечения сексуальных дисфункций у мужчин | |
| TW202317084A (zh) | 新穎治療 | |
| JP2023549605A5 (enExample) | ||
| Katz et al. | Tanezumab, an Anti-Nerve Growth Factor (NGF) antibody, for the treatment of chronic low back pain (CLBP)–a randomized, controlled, double-blind, phase 2 trial | |
| Hanauer et al. | 836 Tofacitinib Efficacy in Patients With Moderate to Severe Ulcerative Colitis: Subgroup Analyses of OCTAVE Induction 1 & 2 and OCTAVE Sustain by 5-Aminosalicylates Use | |
| TW202011949A (zh) | 苯甲酸或其鹽及衍生物用於預防或治療抗ｎ－甲基－ｄ－天冬胺酸受體腦炎之用途 |